Boris Pasche 🇺🇸
President & CEO of the Barbara Ann Karmanos Cancer Institute and Chair of the Department of Oncology at Wayne State University.
First to identify and characterize TGFBR1*6A , an in- frame deletion withing TGFBR1 exon 1 , a low -penetrance tumor susceptibility allele.
First to identify and characterize TGFBR1*6A, a low-penetrance tumor susceptibility allele.
Focus on cancer research and genetic tumor susceptibility.
3:30 PM - 3:50 PM
Day 3 | Oncology Track
Therabionic Cancer Therapy: From Bench to FDA Approval
Contact Us